Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Microglia in Alzheimer's disease
Proliferation and activation of microglia in the brain, concentrated around amyloid plaques,
is a prominent feature of Alzheimer's disease (AD). Human genetics data point to a key role …
is a prominent feature of Alzheimer's disease (AD). Human genetics data point to a key role …
Dissecting the clinical heterogeneity of early-onset Alzheimer's disease
Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Imaging the evolution and pathophysiology of Alzheimer disease
Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …
studies of the relationships between the two major proteins deposited in this disease …
Anti-amyloid therapies for Alzheimer's disease and the amyloid cascade hypothesis
Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
Biomarker modeling of Alzheimer's disease
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …
The evolution of preclinical Alzheimer's disease: implications for prevention trials
As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …
when the pathophysiological process has begun in the brain, but clinical symptoms are not …
Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia
We describe in vivo follow-up PET imaging and postmortem findings from an autosomal
dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for …
dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for …
Tau pathology and neurodegeneration
The pathway leading from soluble and monomeric to hyperphosphorylated, insoluble and
filamentous tau protein is at the centre of many human neurodegenerative diseases …
filamentous tau protein is at the centre of many human neurodegenerative diseases …